Clearmind Medicine签署开发协议，推进其专有无致幻神经塑性药物Meai的鼻内制剂研发

美股速递02-06

Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1173106061?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-06 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173106061","market":"us","top_or_hot":-1,"title":"Clearmind Medicine签署开发协议，推进其专有无致幻神经塑性药物Meai的鼻内制剂研发","media":"美股速递","content":"<p>Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind Medicine签署开发协议，推进其专有无致幻神经塑性药物Meai的鼻内制剂研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind Medicine签署开发协议，推进其专有无致幻神经塑性药物Meai的鼻内制剂研发\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-06 20:56 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1173106061","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173106061","pubTimestamp":1770382573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","PLRZ":"Polyrizon Ltd.","CMND":"Clearmind Medicine, Inc."},"translate_title":"Clearmind Medicine signs development agreement to advance intranasal formulation of its proprietary non-hallucinogenic neuroplastic drug Meai","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":1,"CMND":1},"content_text":"Clearmind Medicine Inc. 近日与Polyrizon Ltd. 达成一项开发合作协议，旨在加速其专有无致幻神经塑性化合物Meai的鼻内制剂研发进程。该合作将结合Clearmind在神经科学领域的专长与Polyrizon在药物递送技术方面的优势，共同推进新型治疗方案的开发。此次合作标志着公司在非致幻性神经可塑性药物研发领域迈出重要一步。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173106061","isCrawlerRequest":true}